Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication ...

周四，Leerink Partners维持了对制药巨头礼来（NYSE:LLY）的"跑赢大市"评级和990.00美元的目标价。该公司的立场是基于英国最近的动向，英国计划评估礼来的药物tirzepatide对肥胖症造成的经济压力的影响。

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...